Stream, Create, Experience: Introducing the DDJ-200
![](https://i1.wp.com/picante.today/wp-content/uploads/2019/05/Pioneer_DJ_logo.jpg?fit=150%2C150&ssl=1)
Smart DJ controller from Pioneer DJ, compatible with streaming
services and our free app WeDJ for iPhone
TORRANCE, Calif.–(BUSINESS WIRE)–Enter the world of DJing with the DDJ-200, our new smartphone and iPhone
compatible smart DJ controller. Priced at just $149 USD, the DDJ-200
makes it easy to start DJing with the help of the Tutorial feature in
our app, WeDJTM for iPhone (ver. 2.0), which you can download
for free from the App Store.
For over 25 years we’ve been making DJ equipment, software, professional
audio gear, and music production tools that have been used by everyone
from bedroom DJs to global stars. Now, the DDJ-200 offers anyone –
regardless of their musical or technical knowledge – an intuitive way to
make the leap into mixing music. Designed with beginners and hobbyists
in mind, the smart DJ controller is compatible with a variety of music
streaming apps and offers access to features that demystify many aspects
of the craft. You can use the DDJ-200 to mix tracks at home or on the go
and take your first steps as an artist.
Connect the DDJ-200 to your iPhone and mix songs from your iTunes via
our app, WeDJ. Or connect the software to SoundCloud Go+ and Beatport’s
new Beatport LINK streaming service to access huge online sources of
music. Download Algoriddim’s djay iOS/Android app and you can mix tracks
from Spotify (Premium account required), or download MWM SAS’s edjing
Mix iOS/Android app and access content from Deezer. Find more
information about iOS/Android app compatibility and music streaming
support below.
The layout of the buttons and dials on the DDJ-200 inherits the style of
our professional DJ equipment to make it simple for you to get hands-on
and find all the controls you need to perform. To help you get to grips
with DJing as quickly as possible, we’ve added the Tutorial and
Transition FX features to WeDJ for iPhone, both of which are popular
with beginners.
The DDJ-200 will be available from mid-May at an MAP of $149 USD. The
smart DJ controller is compatible with WeDJ for iPhone and our
professional performance app for PC/Mac, rekordbox dj (worth $129).
Simply download the software to your compatible device, plug in the
controller and start DJing.
To help keep your DDJ-200 safe from bumps and scrapes on the road, the
DJC-200 BAG will be available (EMEA only, not available in US). The DJ
controller fits snugly into the custom-designed protective bag which
features an EVA Durashock molded body, impact-resistant egg-foam, black
ballistic polyester, and a soft, fleeced lining.
Watch
the DDJ-200 introduction video or find
out more about the smart DJ controller and compatible apps.
KEY FEATURES OF THE DDJ-200 and WeDJ for iPhone
1. Multi-app compatibility and support for
music streaming services
Connect the DDJ-200 to your smartphone, tablet or PC/Mac, choose your
favorite from a number of compatible DJ apps such as WeDJ, MWM SAS’s
edjing Mix and Algoriddim’s djay and control tracks stored on your
device. Some streaming services are supported too, so you can discover
music from numerous genres in vast online catalogs. Even better, when
connected to the DDJ-200, you can enjoy free use of all the features in
rekordbox dj and WeDJ for iPhone that normally incur in-app billing.*1,
2
DDJ-200 compatible DJ apps and their corresponding |
||||||
Application | Supported devices | Compatible streaming service | ||||
WeDJ for iPhone | iPhone | Beatport LINK, SoundCloud Go+ *4 | ||||
djay | iPhone, iPad, Android | Spotify | ||||
edjing Mix | iPhone, iPad, Android | Deezer | ||||
WeDJ for Android*5 | Android | NA | ||||
rekordbox | PC/Mac |
Beatport LINK, SoundCloud Go+ *4
(Both Available in Fall 2019) |
||||
2. Tutorial and Pop-Hint features to help
beginners enjoy DJing
Combine the DDJ-200 with WeDJ for iPhone to use the Tutorial feature
which summarizes the basics of DJing. Find out how to connect the
controller to your devices, and how to use various features and effects,
and pick up tips on performance techniques.
WeDJ for iPhone also offers the Pop-Hint feature that explains the
functions of buttons without switching screens. If you’ve never handled
DJ hardware before, these features will help you get up and running, and
performing, in no time.
3. Transition FX – easily perform professional
sounding mixes with various styles
The DDJ-200 can reproduce various patterns of DJ mixes between tracks
for people with no experience behind the decks. Activate the Transition
FX feature in WeDJ, choose from 11 patterns*7 and simply
slide the crossfader to switch from one track to the next via a
professional-standard transition.
4. Phrase Sync – world’s first feature on a
controller*8 for
easy, natural switches between tracks
Our phrase analysis algorithms will analyze the composition of your
tracks and detect phrases. When you tap the dedicated buttons in WeDJ
for iPhone, Phrase Sync uses the information from this analysis to align
the start and end positions of the phrases in two tracks so you can be
sure it will sound natural when you switch between them. The DDJ-200 is
the world’s first DJ controller to offer this kind of feature.
5. Compact, lightweight body for DJing anytime,
anywhere
Take the DDJ-200 wherever you want, thanks to its lightweight and slim
body. There’s no need to carry speakers because you can play sound from
the built-in speaker of your smartphone, tablet, or PC/Mac. And the DJ
controller can be powered via a power bank*9, so you don’t
even need to stay close to an outlet.
6. Split output for DJ performances
Use split cables to separate the audio output of your smartphone,
tablet, or PC/Mac into master and monitor outputs. This enables you to
check audio via your headphones, e.g., cueing the next track, while the
crowd hears the master sound playing through the speakers.
*1 |
When the DDJ-200 is not connected to the smartphone/tablet/PC/Mac, using paid features of WeDJ for iPhone will incur in-app billing. |
|
*2 |
To use rekordbox dj when the DDJ-200 is not connected, license key activation is required. |
|
*3 |
It is the responsibility of Beatport LINK, Deezer, djay, edjing Mix, SoundCloud Go+, and Spotify users to read terms of use and follow copyright protection laws, rules, and regulations, as well as international treaties designated in the country, where the service is being used. |
|
*4 |
A list of countries where SoundCloud Go+ is available can be found here (as of May 7, 2019). |
|
*5 |
WeDJ for Android is scheduled to become compatible with the DDJ-200 via an update in late July 2019. |
|
*6 & 8 |
The first DJ controller in the DJ controller market (according to research conducted by Pioneer DJ Corporation, May 7, 2019). |
|
*7 | Use of some FX incurs in-app billing. | |
*9 |
Power bank not included. Power banks are external units that can be recharged and carried with smartphones, tablets, and other devices. |
|
DDJ-200 specifications |
||||||
Input / Output Terminals | USB | USB (Type B) x 1 | ||||
Power Supply | USB Bus Powered | |||||
Power Consumption |
DC 5V , 500mA | |||||
Bluetooth | Specification | Bluetooth 4.2 (Low Energy) | ||||
Maximum Dimensions (WxDxH) |
378.0 × 208.0 × 48.2 mm |
|||||
Weight | 1.2 kg / 2.6 lb | |||||
Accessories |
USB cable, Split cable, Warranty (for some regions), Quick Start Guide (WeDJ/rekordbox); Quick Start Guide (djay), Quick Start Guide (edjing Mix) |
|||||
WeDJ for iPhone system requirements |
|||
Compatible OS (iOS) | iOS 12, 11, 10 | ||
iPhone |
iPhone XR,iPhone XS, iPhone XS Max, iPhone X, iPhone 8,iPhone 8 Plus,iPhone 7,iPhone 7 Plus,iPhone SE,iPhone 6s, iPhone 6s Plus, iPhone 6,iPhone 6 Plus, iPhone 5s, iPod touch (6th generation) |
||
rekordbox system requirements |
|||||||
Compatible OS | Mac |
macOS Mojave 10.14 (updated to the latest version) |
|||||
Windows | Windows® 10, 8.1,7 (the latest service pack) | ||||||
CPU |
Intel® processor Core![]() |
||||||
Memory | 4GB or more RAM | ||||||
Visit Algoriddim djay’s official website for its specifications: http://www.algoriddim.com
Visit
MWM SAS’s edjing Mix official website for its specifications: https://www.edjing.com
* Disclaimer: specifications and price are subject to change.
* Use the latest editions of WeDJ for iPhone, rekordbox, and
Algoriddim’s djay and edjing Mix.
* WeDJ is a registered trademark of Pioneer DJ Corporation.
* rekordbox is a registered trademark of Pioneer DJ Corporation.
* Algoriddim, djay and its logo are trade names or registered trademarks
of Algoriddim GmbH.
* Android and Google Play are trademarks of Google Inc.
* App Store is a service mark of Apple Inc.
* Beatport and its logo is a trade name or registered trademark of
Beatport, LLC.
* edjing Mix and its logo are trade names or registered trademarks of
MWM SAS.
* Intel and Intel Core are registered trademarks of Intel Corporation or
its subsidiaries in the U.S. and other countries.
* iOS is a trademark containing Cisco trademark signs in the U.S. and
other countries.
* iPad and iPhone are registered trademarks of Apple Inc. in the U.S.
and other countries.
* Mac, OS X, and macOS are trademarks of Apple Inc., registered in the
U.S. and other countries.
* SoundCloud is a registered trademark of SoundCloud Ltd.
* The Bluetooth® word mark and logos are registered trademarks owned by
the Bluetooth SIG, Inc. and any use of such marks by Pioneer DJ
Corporation is under license.
* Windows is a registered trademark or trademark of Microsoft
Corporation in the U.S. and other countries.
* The names of companies, product names, and technology names mentioned
herein are the trademarks of their respective owners.
* Other stated company names, product names, technology names, etc. are
the trademarks or registered trademarks of their respective owners.
About Pioneer DJ
Pioneer DJ Americas, Inc. is the subsidiary of Pioneer DJ Corporation
responsible for sales and marketing in North, Central, and South
America. For more than 20 years, Pioneer DJ has been a market leader in
the design and production of innovative DJ equipment and software. The
company works closely with DJs and clubs to deliver next generation
products that inspire and shape the global dance music community and has
recently launched a new range of musical instruments for production and
live performances. Its portfolio includes brands such as TORAIZ, Pioneer
Professional Audio and Pioneer DJ Radio, as well as social platforms
KUVO and DJsounds. Pioneer DJ Corporation is a privately held company
headquartered in Yokohama, Japan. The company is led by President and
CEO Akio Moriwaki and Executive Vice President Yoshinori Kataoka.
Website: http://www.pioneerdj.com/
Stay
up to date: http://www.pioneerdj.com/news
USA Social Media:
- Facebook at facebook.com/PioneerDJUSA
-
Facebook at facebook.com/PioneerDJUSAInstagram
at instagram.com/PioneerDJUSA - Instagram at instagram.com/TORAIZGLOBAL
- Twitter at twitter.com/PioneerDJ
- YouTube at youtube.com/pioneerdjglobal
Contacts
Christina Roach, 503.290.7310, [email protected]
![](https://grassnews.net/wp-content/uploads/2019/03/Grassnews-600px.png)
Indivior
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (AS IT FORMS PART OF DOMESTIC LAW IN THE UK BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018).
- Primary and Secondary End Points of the Study were Not Met
- Indivior Does Not Currently Expect to Exercise AEF0117 Option
SLOUGH, United Kingdom and RICHMOND, Va., Sept. 4, 2024 /PRNewswire/ — Indivior PLC (Nasdaq/LSE: INDV) is today providing an update following Aelis Farma’s announcement of the results from its clinical Phase 2B trial with AEF01171, evaluating the efficacy and safety in treatment-seeking participants with moderate to severe Cannabis Use Disorder (CUD). The purpose of this trial was twofold: (1) to show that AEF0117 (0.1, 0.3, 1 mg once a day for 12 weeks) lowers cannabis use and (2) to determine the endpoints and optimal dosage of AEF0117 for use in future studies. In this phase 2B study, patients were treatment-seeking participants, 84% of whom had severe CUD.
The results of the study demonstrated that the primary endpoint, the proportion of participants who reduced their cannabis use to ≤1 day per week, as well as secondary endpoints measuring the proportion of participants reaching either complete abstinence or who used ≤2 day per week, were not met. Although these results are disappointing, they indicate that significant work remains to be done to understand subpopulations of patients with CUD, specifically those with severe CUD.
This clinical Phase 2B study is part of the strategic collaboration between Aelis Farma and Indivior, which includes an exclusive option for Indivior to license the global rights to AEF0117. Given the lack of separation from placebo on primary and secondary endpoints and before seeing further additional favorable clinical data, Indivior does not currently expect to exercise its option.
Important Cautionary Note Regarding Forward-Looking Statements
This news release contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding whether: we will be able to ultimately demonstrate the safety and efficacy of AEF0117, which is a prerequisite to filing any New Drug Application; we might ever exercise our option for AEF0117 and, if so, when; and other statements containing the words “believe,” “anticipate,” “plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,” “project,” “priority,” “may,” “will,” “should,” “would,” “could,” “can,” “outlook,” “guidance,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.
Actual results may differ materially from those because they relate to future events. Various factors may cause differences between Indivior’s expectations and actual results, including, among others, the risks described in our most recent annual report on Form 20-F beginning on page 9 as filed with the U.S. SEC and in subsequent releases; legal and market restrictions that may limit how quickly we can repurchaser our shares; the substantial litigation and ongoing investigations to which we are or may become a party; our reliance on third parties to manufacture commercial supplies of most of our products, conduct our clinical trials and at times to collaborate on products in our pipeline; our ability to comply with legal and regulatory settlements, healthcare laws and regulations, requirements imposed by regulatory agencies and payment and reporting obligations under government pricing programs; risks related to the manufacture and distribution of our products, most of which contain controlled substances; market acceptance of our products as well as our ability to commercialize our products and compete with other market participants; competition; the uncertainties related to the development of new products, including through acquisitions, and the related regulatory approval process; our dependence on third-party payors for the reimbursement of our products and the increasing focus on pricing and competition in our industry; unintended side effects caused by the clinical study or commercial use of our products; our ability to successfully execute acquisitions, partnerships, joint ventures, dispositions or other strategic acquisitions; our ability to protect our intellectual property rights and the substantial cost of litigation or other proceedings related to intellectual property rights; the risks related to product liability claims or product recalls; the significant amount of laws and regulations that we are subject to, including due to the international nature of our business; macroeconomic trends and other global developments such as armed conflicts and pandemics; the terms of our debt instruments, changes in our credit ratings and our ability to service our indebtedness and other obligations as they come due; changes in applicable tax rate or tax rules, regulations or interpretations and our ability to realize our deferred tax assets; and volatility in our share price due to factors unrelated to our operating performance or that may result from the potential move of our primary listing to the U.S.
Forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.
This release is being made by Kathryn Hudson, Company Secretary Indivior PLC.
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD), overdose and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.
References:
- National Library of Medicine (U.S.) (2022, April). Effect of AEF0117 on treatment-seeking patients with cannabis use disorder (CUD) (SICA2). Identifier
NCT05322941 https://www.clinicaltrials.gov/study/NCT05322941
Logo – https://mma.prnewswire.com/media/1814851/Indivior_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/indivior-provides-update-on-aelis-farmas-clinical-phase-2b-study-results-with-aef0117-in-participants-with-cannabis-use-disorder-302237355.html
Innocan
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
![innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options](https://grassnews.net/wp-content/uploads/2024/08/61828-innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options.jpg)
HERZLIYA, Israel and CALGARY, Alberta, Aug. 29, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that it has completed its previously announced non-brokered private placement offering of 5,025,725 units of the Company (the “Units”) at a price of C$0.22 per Unit for gross proceeds of C$1,105,659.50 (the “Offering”).
Each Unit is comprised of: (i) one (1) common share in the capital of the Company (each a “Common Share”); and (ii) one (1) common share purchase warrant (each a “Warrant”). Each Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.32 for a period of four (4) years from the date of issuance.
Innocan intends to use the proceeds of the Offering for working capital and general corporate purposes.
The securities issued to Canadian subscribers in connection with the Offering are subject to a hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.
Iris Bincovich, Chief Executive Officer of the Company, stated “we are very pleased with our successful offering. I would like to extend my sincere gratitude to our investors for their unwavering support. We see this as a strong vote of confidence by both existing and new investors which demonstrates investor support of our vision and strategic direction. These new funds will provide us with additional working capital to enable us to capitalize on new opportunities and allow us to advance strongly on our growth plans.”
The Company is also pleased to announce that it has granted an aggregate of 300,000 stock options (each an “Option“) to certain consultants of the Company pursuant to the Company’s stock option plan (the “Plan“). Each Option may be exercised for one (1) common share in the capital of the Company (each, a “Share“) at a price of $0.25 per Share. The Options expire on August 27, 2029.
All Options granted vest in accordance with the following vesting schedule: (i) 1/3rd of the Options vested immediately at grant; (ii) 1/3rd of the Options will vest on February 28, 2025; and (iii) 1/3rd will vest on August 27, 2025; all subject to the terms and conditions of the Plan.
About Innocan Pharma:
Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/
Contact Information:
For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
[email protected]
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
Logo – https://mma.prnewswire.com/media/2046271/4883982/Innocan_Pharma_Corporation_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-closing-of-private-placement-and-grant-of-stock-options-302234455.html
Cannabis
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
![](https://grassnews.net/wp-content/uploads/2024/08/europe-medical-cannabis-market-forecast-2024-2032-tilray-aurora-cannabis-and-gw-pharmaceuticals-dominate-the-market-landscape.gif)
Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.
The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:
- Derivatives;
- Source;
- Application;
- Route of Administration;
- End-user;
- Distribution Channel; and
- Country.
Market Highlights Identified in the Report
- Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
- Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
- Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.
The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.
Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.
Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.
Regional Insights
Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.
Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.
Competitive Landscape
The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.
The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.
Key Topics Covered
Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)
A selection of companies mentioned in this report includes, but is not limited to:
- Aurora Cannabis Inc.
- Bedrocan
- Biocann
- BIOTA Biosciences LLC
- Cannamedical
- Mary Jane CBD
- Sanity Group GmbH
- Tilray
- Valcon Medical
For more information about this report visit https://www.researchandmarkets.com/r/dh7q46
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
-
Cannabis2 weeks ago
Silly Nice Announces Launch of New 1G 510 Vape Cartridge and 2G All-In-One Vape in New York Dispensaries This September
-
Cannabis2 weeks ago
Cannabis Cultivation Market – Global Food Additives, Oils, Tinctures, Cannabis Indica, Cannabis Sativa Forecast 2024-2030
-
Cannabis1 week ago
Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape
-
Cannabis2 weeks ago
Global Hemp Based Food Market Size To Worth USD 4.87 Billion By 2033 | CAGR Of 13.12%
-
Innocan1 week ago
Innocan Pharma Announces Closing of Private Placement and Grant of Stock Options
-
Indivior4 days ago
Indivior Provides Update on Aelis Farma’s Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder